文献速递帕金森病与运动障碍

SURE-PD试验中性别差异对肌苷升高尿酸反应及结局的影响

Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial.
PubMed 文献 · Neurology · 2019-09-04

SURE-PD试验纳入75例早期帕金森病且基线血尿酸低于6 mg/dL的患者,随机接受安慰剂或肌苷滴定至轻度或中度血尿酸升高,治疗至多2年。二次分析按性别分层发现,肌苷使女性平均血尿酸绝对升幅(3.0 mg/dL)比男性(2.0 mg/dL)高50%,仅女性脑脊液尿酸显著升高,且较高剂量组女性UPDRS年下降率较安慰剂低7.0分。

要点

  • 肌苷升高血尿酸的幅度女性大于男性。
  • 仅女性脑脊液尿酸在肌苷治疗下显著升高。
  • 较高剂量肌苷或减缓女性早期帕金森病进展。

核心结论

  • 在SURE-PD试验中,肌苷使女性血尿酸和脑脊液尿酸升高幅度大于男性,与女性临床下降较慢的初步证据一致。

研究设计与样本

  • SURE-PD试验纳入75例早期帕金森病且基线血尿酸低于6 mg/dL的患者,随机分入口服安慰剂或肌苷滴定至轻度(6.1-7.0 mg/dL)或中度(7.1-8.0 mg/dL)血尿酸升高组,治疗至多2年,本报告为按性别分层的二次分析。

主要发现

  • 肌苷引起的平均血尿酸绝对升幅女性为3.0 mg/dL,男性为2.0 mg/dL,女性比男性高50%。
  • 仅女性在轻度或中度肌苷组脑脊液尿酸显著高于安慰剂组(分别+87% [p < 0.001]和+98% [p < 0.001]),男性无显著差异(+10% [p = 0.6]和+14% [p = 0.4])。
  • 较高剂量肌苷组女性UPDRS年下降率较安慰剂组低7.0分/年(p = 0.01)。
  • 女性中UPDRS变化速率较慢与血尿酸升高幅度较大相关(r = -0.52;p = 0.001),也与血浆抗氧化能力升高幅度较大相关(r = -0.44;p = 0.006),男性无显著关联。

临床怎么用

  • 对于早期帕金森病女性患者,肌苷升高尿酸的治疗可能更显著地改善脑脊液尿酸暴露并减缓临床进展,但需在临床研究中进一步验证。

局限性

  • 本研究为二次分析,样本量有限,结果需在更大规模试验中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate whether women and men with Parkinson disease (PD) differ in their biochemical and clinical responses to long-term treatment with inosine. METHODS: The Safety of Urate Elevation in Parkinson's Disease (SURE-PD) trial enrolled 75 people with early PD and baseline serum urate below 6 mg/dL and randomized them to 3 double-blinded treatment arms: oral placebo or inosine titrated to produce mild (6.1-7.0 mg/dL) or moderate (7.1-8.0 mg/dL) serum urate elevation for up to 2 years. Parkinsonism, serum urate, and plasma antioxidant capacity were measured at baseline and repeatedly on treatment; CSF urate was assessed once, at 3 months. Here in secondary analyses results are stratified by sex. RESULTS: Inosine produced an absolute increase in average serum urate from baseline that was 50% greater in women (3.0 mg/dL) than in men (2.0 mg/dL), consistent with expected lower baseline levels in women. Similarly, only among women was CSF urate significantly greater on mild or moderate inosine (+87% [p < 0.001] and +98% [p < 0.001], respectively) than on placebo (in contrast to men: +10% [p = 0.6] and +14% [p = 0.4], respectively). Women in the higher inosine dosing group showed a 7.0 Unified Parkinson's Disease Rating Scale (UPDRS) points/year lower rate of decline vs placebo (p = 0.01). In women, slower rates of UPDRS change were associated with greater increases in serum urate (r = -0.52; p = 0.001), and with greater increases in plasma antioxidant capacity (r = -0.44; p = 0.006). No significant associations were observed in men. CONCLUSIONS: Inosine produced greater increases in serum and CSF urate in women compared to men in the SURE-PD trial, consistent with the study's design and with preliminary evidence for slower clinical decline in early PD among women treated with urate-elevating doses of inosine. CLINICALTRIALSGOV IDENTIFIER: NCT00833690. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that inosine produced greater urate elevation in women than men and may slow PD progression in women.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Schwarzschild MA, Macklin EA, Bakshi R, et al. Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. Neurology. 2019. PMID: 31484712. doi:10.1212/WNL.0000000000008194

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。